Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Chlamydia Pneumoniae Seropositivity in Iranian Patients With Multiple Sclerosis: A Pilot Study; [Obecnosc Przeciwcial Przeciw Chlamydia Pneumoniae Wsrod Iranskich Chorych Na Stwardnienie Rozsiane: Badanie Pilotazowe] Publisher



Aghaei M1 ; Ashtari F2 ; Bahar M3 ; Falahian MR1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Science and Research Branch, Islamic Azad University, Tehran, Iran
  2. 2. Department of Neurology, Kashani MS Clinic, Kashani Hospital, Isfahan Neuroscience Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Immunology, Iran University of Medical Sciences and Health Services, Tehran, Iran

Source: Neurologia i Neurochirurgia Polska Published:2011


Abstract

Background and purpose: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Genetic and environmental factors could not completely explain the pathogenesis of the disease. Among environmental factors, infectious agents are of more interest than other candidates, so Chlamydia pneumoniae (C. pneumoniae) may have a role in MS development or progression. This study aimed to evaluate C. pneumoniae seropositivity in MS patients. Material and methods: Serum samples obtained from a cohort of 85 patients with MS and from 50 age- and sex-matched controls were assessed for the presence of antibodies. IgM and IgG concentration for C. pneumoniae were determined with enzyme-linked immunosorbent assay (ELISA). Results: The mean age was 33.8 (9.96) years in the MS group and 33.9 (10.7) years in controls. Female/male ratio was 3.5: 1 in the MS group; 69 patients (81%) had relapsing-remitting course (RRMS) and 16 patients (19%) had secondary progressive course (SPMS). The median concentration of C. pneumoniae IgM in the MS group was 0.5 RU/mL (0.25-1) versus 0.5 RU/mL (0.3-0.8) in the control group (p = 0.66); likewise, the median concentration of C. pneumoniae IgG in MS patients was 57.3 RU/mL (17.05-95.1) compared with 56.15 RU/mL (6.85-102.5) in the control group (p = 0.85). Regarding the clinical course, C. pneumoniae IgG was 55.1 RU/mL (20.7-88.6) in RRMS and 59.1 RU/mL (5.35-112) in SPMS (p = 0.8). Conclusion: No association was observed between MS and C. pneumoniae in Iranian MS patients.
Related Docs
View other Related Docs
1. Serum Uric Acid Level in Patients With Relapsing-Remitting Multiple Sclerosis, Journal of Clinical Neuroscience (2013)
2. Cytomegalovirus Seroposivity in Iranian Multiple Sclerosis: A Randomized Case-Control Study, Pakistan Journal of Medical Sciences (2012)
3. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
4. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
5. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
6. Incidence and Prevalence of Multiple Sclerosis in Persian Gulf Area: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2020)
7. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
8. Ongoing Increase in Incidence and Prevalence of Multiple Sclerosis in South-Eastern Iran: A Three Decade Study, Multiple Sclerosis and Related Disorders (2023)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (61)
Vahid Shaygannejad (43)
Other Related Docs
9. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)
10. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
11. Interleukin 18 Polymorphisms and Its Serum Level in Patients With Multiple Sclerosis, Annals of Indian Academy of Neurology (2019)
12. Cytomegalovirus and Varicella Zoster Virus Seropositivity of Iranian Patients With Multiple Sclerosis: A Population-Based Study, Journal of Neuroimmunology (2017)
13. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
14. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
15. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
16. Elevated Serum Level of Il-4 in Neuromyelitis Optica and Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
17. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
18. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
19. Decreased Serum Levels of Interleukin-35 Among Multiple Sclerosis Patients May Be Related to Disease Progression, Journal of Biological Regulators and Homeostatic Agents (2018)
20. Self-Reported Safety of the Bbibp-Corv (Sinopharm) Covid-19 Vaccine Among Iranian People With Multiple Sclerosis, Human Vaccines and Immunotherapeutics (2022)
21. Serum Mercury Level and Multiple Sclerosis, Biological Trace Element Research (2012)
22. Risk Factors of Multiple Sclerosis and Their Relation With Disease Severity: A Cross-Sectional Study From Iran, Archives of Iranian Medicine (2016)
23. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
24. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
25. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
26. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
27. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
28. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
29. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
30. Chlamydia Pneumoniae Infection and Thrombotic Ischemic Stroke, Journal of Isfahan Medical School (2007)
31. Elevated Csf Concentration of Ccl3 and Ccl4 in Relapsing Remitting Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
32. Pemphigus Vulgaris in a Patient With Multiple Sclerosis: A Case Report With 7 Years of Follow Up, Journal of Research in Dental and Maxillofacial Sciences (2023)
33. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
34. The Global Prevalence of Familial Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis, BMC Neurology (2021)
35. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
36. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
37. Comparing the Frequency of Tim-3 Polymorphism in Multiple Sclerosis Patients With Healthy Controls, Journal of Isfahan Medical School (2015)
38. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
39. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)
40. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
41. Higher Latitude Is Significantly Associated With an Earlier Age of Disease Onset in Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2016)
42. Pure Spinal Multiple Sclerosis: A Case Series of a Possible New Entity, Journal of Neuroimmunology (2025)
43. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
44. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
45. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
46. The Beneficial Effects of Vitamin D3 on Reducing Antibody Titers Against Epstein-Barr Virus in Multiple Sclerosis Patients, Cellular Immunology (2015)
47. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
48. Important Factors Influencing Severity of Common Variable Immunodeficiency, Archives of Iranian Medicine (2016)
49. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
50. Myasthenia Gravis During the Course of Neuromyelitis Optica, Case Reports in Neurology (2011)